Monitoring Agency Report

Date: November 06, 2026 BSE Limited(“BSE”) National Stock Exchange of India Ltd(“NSE”) Phiroze Jeejeebhoy Towers Exchange Plaza 2nd Floor, Dalal Street Bandra-Kurla Complex, Bandra (E) Mumbai- 400001 Mumbai- 400051 BSE Scrip Code: 544866 Symbol: MOLBIO Subject: Monitoring Agency Report on the utilization of proceeds raised through issuance of equity shares by way of Public Issue of the Company. Dear Sir/Madam, Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) read with Regulations 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”), please find enclosed the Monitoring Agency Report issued by CRISIL Ratings Limited (Monitoring Agency), in respect to utilization of the proceeds raised through issuance of equity shares by way of Initial Public Offering (IPO) of the Company for the quarter ended September 30, 2026 duly reviewed and taken on record by the Audit Committee and Board of Directors of the Company at their meetings held on November 05, 2026. The above disclosure is also being made available on the website of the Company at https://www.molbiodiagnostics.com/investors/ This is for your information and records. Thanking You. Yours Faithfully, For Molbio Diagnostics Limited Darshan Raghunath Karekar Company Secretary & Compliance Officer M. No: F13569 Place: Verna-Goa Monitoring Agency Report Molbio Diagnostics Limited for the quarter ended September 30, 2026 CRL/MAR/ MODPTL/2026-27/2064 November 06, 2026 Molbio Diagnostics Limited Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa 403 722, Goa, India Dear Sir/Ma’am, Monitoring Agency Report for the quarter ended September 30, 2026 - in relation to the Initial Public Offer (“IPO”) of Molbio Diagnostics Limited (“the Company”) Pursuant to Regulation 41 (2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated July 24, 2026, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended September 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Molbio Diagnostics Limited For quarter ended: September 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Molbio Diagnostics Limited Names of the promoter: Mr. Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair Mrs. Sangeetha Sriram, Mr. Shiva Sriram, Mrs. Sowmya Sriram, Exxora Trading LLP Industry/sector to which it belongs: Medical Equipment & Supplies 2) Issue Details Issue Period: August 07, 2026, to August 12, 2026 Type of issue (public/rights): Initial Public Offer (IPO) Type of specified securities: Equity Shares IPO Grading, if any: NA Issue size: Rs 2,000.00 million* *Note: Particulars Amount (Rs in million) Gross proceeds 2,000.00# Less: Issue Expenses 127.19 Net Proceeds 1,872.81 #Crisil Ratings shall be monitoring the gross proceeds. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ Comments certifications Comments of the Monitoring of the Particulars Reply considered by Agency Board of Monitoring Agency Directors for preparation of report Management undertaking, Peer reviewed Independent Chartered Whether all utilization is as per accountant Proceeds were utilized towards No the disclosures in the Offer Yes certificate^, funding capital expenditure comments Document? Prospectus dated 12/08/2026 (hereinafter referred to as “Offer document”), Bank Statements Whether shareholder approval has been obtained in case of material deviations from NA No comments comments expenditures disclosed in the Offer Document? Whether the means of finance for the disclosed objects of the issue No No comments comments has changed? Is there any major deviation observed over the earlier NA No comments comments monitoring agency reports? Management Whether all Government/ Undertaking, No statutory approvals related to the NA No comments Peer reviewed comments object(s) have been obtained? Independent Whether all arrangements Chartered pertaining to technical No NA accountant No comments assistance/collaboration are in comments certificate^ operation? Are there any favorable events improving the viability of these No No comments comments object(s)? Are there any unfavorable events affecting the viability of the No No comments comments object(s)? Is there any other relevant information that may materially No No No comments affect the decision making of the comments investors? NA represents Not Applicable ^Certificate dated October 14, 2026, issued by M/s. Vinay Bhushan and Associates (Firm Registration Number: 130529W), Peer reviewed Independent Chartered accountant. 4) Details of object(s) to be monitored: i. Cost of the object(s): Source of Original Comments of the Board of Directors information/ cost Revised Comment of certification (as per the Particulars of Sr. Cost the Reason Proposed Item considered by Offer firm No. (Rs in Monitoring of Cost financing Head MA for Document) arrangements million) Agency revision option preparation of (Rs in made report million) Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of 1 Excellence which will 1,055.35 - No revision No comments be operated by the wholly-owned Management Subsidiary, Bigtec a [Showing first 8,000 characters — download PDF for full document]